scispace - formally typeset
D

David R. Compton

Researcher at VCU Medical Center

Publications -  44
Citations -  6487

David R. Compton is an academic researcher from VCU Medical Center. The author has contributed to research in topics: Cannabinoid & Cannabinoid receptor. The author has an hindex of 25, co-authored 43 publications receiving 6244 citations. Previous affiliations of David R. Compton include Clemson University & Research Triangle Park.

Papers
More filters
Journal Article

Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.

TL;DR: Although most of the chosen compounds did not discriminate between CB1 and CB2, several ligands were identified that showed selectivity and can now serve as a basis for the design of compounds with even greater selectivity.
Journal Article

Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

TL;DR: High correlations were demonstrated between binding affinity and in vivo potency in both the rat drug discrimination model and for psychotomimetic activity in humans, and the structure-activity relationship indicated the importance of side chain structure to high-affinity binding.
Journal Article

In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.

TL;DR: It is not clear whether this pharmacological activity represents an uncharacterized action of SR141716A, or an index of tonic activity of an endogenous cannabinergic system, but it will be useful in establishing the biochemical events responsible for the in vivo effects of exogenous cannabinoids, as well as inestablishing the existence of a putative endogenous cannabinoidergic system.
Journal Article

Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol.

TL;DR: Six novel aminoalkylindole analogs, related structurally to the dual cyclooxygenase inhibitor and nonopioid analgesic pravadoline, were evaluated in the mouse to determine whether their pharmacological profile of activity was similar to that exhibited by delta 9-tetrahydrocannabinol (delta 9-THC).